← Back
Data updated: Mar 29, 2026
MANNKIND
MetabolicInfectious DiseaseRespiratory
Biotech
MANNKIND is a biotechnology company focused on Metabolic, Infectious Disease, Respiratory. Key products include AFREZZA.
2014
Since
1
Drugs
-
Trials
1
Approved (2yr)
Top Drug Revenues Pro
Loading...
Revenue Over Time Pro
Loading...
Therapeutic Areas
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Metabolic 73%
1 drugs Phase 3: 1 Phase 2: 2 Phase 1: 5
Infectious Disease 15%
0 drugs Phase 3: 1
Respiratory 8%
0 drugs Phase 1: 2
Cardiovascular 4%
0 drugs Phase 1: 1
Pipeline Forecast
Loading...
Loading...
Upcoming Trial Milestones Pro
Loading...
Patent Cliff Pro
Loading...
Loading...
Loading...
Competitors by Therapeutic Area
Merck big-pharma
Infectious Disease, Cardiovascular, Metabolic
Johnson & Johnson big-pharma
Infectious Disease, Cardiovascular, Metabolic
Sanofi big-pharma
Metabolic, Infectious Disease, Respiratory
B BRAUN specialty
Infectious Disease, Metabolic, Cardiovascular
AstraZeneca big-pharma
Respiratory, Cardiovascular, Metabolic
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2014-06-27
- Latest
- 2026-01-23
- Applications
- 1